Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2009.

Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $33.4 million or $0.36 per share in the second quarter of 2008.

Nektar made improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in the second quarter of 2008. For the first half of 2009, total operating costs and expenses were down 28% to $83.5 million as compared to $115.6 million in the first half of 2008.

"In the first half of 2009, we made a strong commitment to advancing our clinical pipeline," stated Howard W. Robin, President and Chief Executive Officer of Nektar. "We completed our Phase 2 clinical program for NKTR-118, and we are poised to report Phase 2 data for NKTR-102 and Phase 1 data for NKTR-105 by year-end. These achievements underscore the strength of Nektar's drug development organization and our successful strategy to focus on developing proprietary drugs with our advanced polymer conjugate technology."

Research and development expense was $24.2 million in the second quarter of 2009 as compared to $33.5 million for the same quarter in 2008. For the first half of 2009, research and development expense was $48.0 million as compared to $70.9 million for the first half of 2008. Included in the $48.0 million of overall research and development expense in the first half of 2009 is approximately $27.4 million of investment in Nektar preclinical and clinical development programs.

Revenue for the three month period ende
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... subset analyses of progression-free survival in,the SPARC ... in,relative risk of disease progression for patients ... as well as presence or absence of ... Pharmion,Corporation and GPC Biotech AG today announced ...
... Results in Improved Long-term [Five-years],Overall Survival for ... 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, ... survival (OS) and,time to disease progression (TTP) ... in patients with metastatic (advanced) colorectal cancer.,Importantly, ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4
(Date:8/28/2015)... ... ... An online provider of CPAP machines, masks, supplies, and accessories, My Cpap ... by offering shipping at no cost to you, directly to your door on all ... My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is a ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The ... the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of ... Emanuel. , “With the help of the medical community and the University ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... the safety of a potential vaccine against mesothelioma, a ... which infuses uses a patient,s own dendritic cells (DC) ... induce a T-cell response against mesothelioma tumors. "[This] ... patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., ...
... A new iPhone app designed ... gone on sale on the App Store , ... (PRWeb UK) March 3, 2010 -- The Quickka Calories PRO iPhone app is aimed at ... items that they eat., , ,In what is being called a perfect union between technology and ...
... ... ... ... ...
... ... , ... , , , ... HOUSTON , March ...
... University of Texas M. D. Anderson Cancer Center, researchers found ... bladder cancer, is a cost-effective method of detecting tumors. ... well as the number of false positives that may result ... The study was presented today in advance of the American ...
... University of Washington,s Dr. H. Hunter Handsfield, a long-time ... the nation,s highest honor in the STD field during ... STD Prevention Conference in Atlanta, March 8-11. Handsfield ... named for Dr. Thomas Parran, Jr., U.S. Surgeon General ...
Cached Medicine News:Health News:Possible vaccine for mesothelioma proven safe 2Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 3Health News:Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants 2Health News:Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 3Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 4
... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
Medicine Products: